Abstract | BACKGROUND: OBJECTIVE: MATERIALS AND METHODS: RESULTS:
Erenumab, fremanezumab, galcanezumab, and eptinezumab have all undergone phase 3 trials and have been found to be effective for episodic and chronic migraine. They have the advantage of being targeted therapies for migraine with very favorable adverse effect profiles comparable to placebo. Importantly, they are effective in subgroups of patients who have failed previous preventive therapies. CONCLUSION: Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.
|
Authors | Karthik Nagaraj, Nicolas Vandenbussche, Peter J Goadsby |
Journal | Neurology India
(Neurol India)
2021 Mar-Apr
Vol. 69
Issue Supplement
Pg. S59-S66
ISSN: 1998-4022 [Electronic] India |
PMID | 34003149
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Calcitonin
- Calcitonin Gene-Related Peptide
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Calcitonin
- Calcitonin Gene-Related Peptide
- Calcitonin Gene-Related Peptide Receptor Antagonists
(therapeutic use)
- Humans
- Migraine Disorders
(drug therapy, prevention & control)
|